• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance.设计一种强效的 D-肽 HIV-1 进入抑制剂,具有很强的抗耐药性。
J Virol. 2010 Nov;84(21):11235-44. doi: 10.1128/JVI.01339-10. Epub 2010 Aug 18.
2
Characterization of resistance to a potent D-peptide HIV entry inhibitor.耐药性对强效 D-肽 HIV 进入抑制剂的影响。
Retrovirology. 2019 Oct 22;16(1):28. doi: 10.1186/s12977-019-0489-7.
3
Design of a modular tetrameric scaffold for the synthesis of membrane-localized D-peptide inhibitors of HIV-1 entry.设计一种用于合成定位于膜的 HIV-1 进入抑制剂的四聚体模块化支架。
Bioconjug Chem. 2012 Jun 20;23(6):1252-8. doi: 10.1021/bc300076f. Epub 2012 May 17.
4
Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.HIV-1对靶向Gp41口袋的短肽融合抑制剂的耐药机制
J Virol. 2015 Jun;89(11):5801-11. doi: 10.1128/JVI.00373-15. Epub 2015 Mar 18.
5
Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.人类免疫缺陷病毒1型对靶向Gp41口袋的新型融合抑制剂耐药的遗传途径
J Virol. 2015 Dec;89(24):12467-79. doi: 10.1128/JVI.01741-15. Epub 2015 Oct 7.
6
Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket.靶向gp41口袋的高效HIV-1融合抑制剂的设计
AIDS. 2015 Jan 2;29(1):13-21. doi: 10.1097/QAD.0000000000000498.
7
Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.HIV-1抑制肽T20与gp41 N-HR卷曲螺旋的相互作用
J Biol Chem. 2009 Feb 6;284(6):3619-27. doi: 10.1074/jbc.M809269200. Epub 2008 Dec 10.
8
Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.创建人工尾部锚定物作为增强基于肽的HIV融合抑制剂效力的新策略。
J Virol. 2016 Dec 16;91(1). doi: 10.1128/JVI.01445-16. Print 2017 Jan 1.
9
The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance.M-T钩结构增强了HIV-1融合抑制剂西夫韦肽的效力并克服了耐药性。
J Antimicrob Chemother. 2014 Oct;69(10):2759-69. doi: 10.1093/jac/dku183. Epub 2014 Jun 7.
10
Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.基于恩夫韦肽(T20)的脂肽是一种有效的HIV-1细胞融合抑制剂:对病毒进入和抑制的意义。
J Virol. 2017 Aug 24;91(18). doi: 10.1128/JVI.00831-17. Print 2017 Sep 15.

引用本文的文献

1
Innovative Peptide Therapeutics in the Pipeline: Transforming Cancer Detection and Treatment.正在研发的创新肽疗法:变革癌症检测与治疗
Int J Mol Sci. 2025 Jul 16;26(14):6815. doi: 10.3390/ijms26146815.
2
Utilizing Machine Learning to Improve Neutralization Potency of an HIV-1 Antibody Targeting the gp41 N-Heptad Repeat.利用机器学习提高靶向gp41 N-七肽重复序列的HIV-1抗体的中和效力。
ACS Chem Biol. 2025 Jul 18;20(7):1470-1480. doi: 10.1021/acschembio.5c00035. Epub 2025 Jun 20.
3
Generating a mirror-image monobody targeting MCP-1 via TRAP display and chemical protein synthesis.通过TRAP展示和化学蛋白质合成生成靶向单核细胞趋化蛋白-1(MCP-1)的镜像单域抗体。
Nat Commun. 2024 Dec 23;15(1):10723. doi: 10.1038/s41467-024-54902-x.
4
Electron tomography visualization of HIV-1 virions trapped by fusion inhibitors to host cells in infected tissues.电子断层扫描可视化感染组织中融合抑制剂捕获的 HIV-1 病毒颗粒。
J Virol. 2024 Nov 19;98(11):e0143224. doi: 10.1128/jvi.01432-24. Epub 2024 Oct 30.
5
The Role of Peptides in Combatting HIV Infection: Applications and Insights.肽在抗击 HIV 感染中的作用:应用与见解。
Molecules. 2024 Oct 19;29(20):4951. doi: 10.3390/molecules29204951.
6
BracketMaker: Visualization and optimization of chemical protein synthesis.支架生成器:化学蛋白质合成的可视化和优化。
Protein Sci. 2024 Oct;33(10):e5174. doi: 10.1002/pro.5174.
7
Structure and Interactions of HIV-1 gp41 CHR-NHR Reverse Hairpin Constructs Reveal Molecular Determinants of Antiviral Activity.HIV-1 gp41 CHR-NHR 反向发夹结构与相互作用揭示了抗病毒活性的分子决定因素。
J Mol Biol. 2024 Aug 15;436(16):168650. doi: 10.1016/j.jmb.2024.168650. Epub 2024 Jun 10.
8
Deciphering the Synthetic and Refolding Strategy of a Cysteine-Rich Domain in the Tumor Necrosis Factor Receptor (TNF-R) for Racemic Crystallography Analysis and d-Peptide Ligand Discovery.解析肿瘤坏死因子受体(TNF-R)中富含半胱氨酸结构域的合成与重折叠策略用于外消旋晶体学分析和d-肽配体发现。
ACS Bio Med Chem Au. 2023 Dec 11;4(1):68-76. doi: 10.1021/acsbiomedchemau.3c00060. eCollection 2024 Feb 21.
9
Strategies to improve the physicochemical properties of peptide-based drugs.提高基于肽的药物理化性质的策略。
Pharm Res. 2023 Mar;40(3):617-632. doi: 10.1007/s11095-023-03486-0. Epub 2023 Mar 3.
10
HIV-1 prehairpin intermediate inhibitors show efficacy independent of neutralization tier.HIV-1 发夹前中间体抑制剂的疗效不依赖中和作用。
Proc Natl Acad Sci U S A. 2023 Feb 21;120(8):e2215792120. doi: 10.1073/pnas.2215792120. Epub 2023 Feb 16.

本文引用的文献

1
Processing of X-ray diffraction data collected in oscillation mode.振荡模式下收集的X射线衍射数据的处理。
Methods Enzymol. 1997;276:307-26. doi: 10.1016/S0076-6879(97)76066-X.
2
Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance.评估底物-囊泡假说:设计用于抵抗耐药性的新型 HIV-1 蛋白酶抑制剂的结构分析。
J Virol. 2010 May;84(10):5368-78. doi: 10.1128/JVI.02531-09. Epub 2010 Mar 17.
3
Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding.融合抑制剂结合后 HIV-1 gp41 的不对称失活。
PLoS Pathog. 2009 Nov;5(11):e1000674. doi: 10.1371/journal.ppat.1000674. Epub 2009 Nov 26.
4
Phaser crystallographic software.相位结晶学软件。
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674. doi: 10.1107/S0021889807021206. Epub 2007 Jul 13.
5
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.雷特格韦用于耐药HIV-1感染的亚组分析和耐药性分析。
N Engl J Med. 2008 Jul 24;359(4):355-65. doi: 10.1056/NEJMoa0708978.
6
Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants.选择多种具有临床相关性的整合酶抑制剂耐药1型人类免疫缺陷病毒突变体。
Antiviral Res. 2008 Nov;80(2):213-22. doi: 10.1016/j.antiviral.2008.06.012. Epub 2008 Jul 14.
7
Selection of T1249-resistant human immunodeficiency virus type 1 variants.T1249耐药的1型人类免疫缺陷病毒变体的选择
J Virol. 2008 Jul;82(13):6678-88. doi: 10.1128/JVI.00352-08. Epub 2008 Apr 23.
8
Potent D-peptide inhibitors of HIV-1 entry.强效的HIV-1进入的D肽抑制剂。
Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):16828-33. doi: 10.1073/pnas.0708109104. Epub 2007 Oct 17.
9
Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.具有抗恩夫韦肽耐药病毒活性的螺旋寡聚HIV-1融合抑制剂肽的设计
Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. doi: 10.1073/pnas.0701478104. Epub 2007 Jul 19.
10
Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.全球流行的1型人类免疫缺陷病毒亚型分布:对发病机制和治疗的影响
J Virol. 2007 Oct;81(19):10209-19. doi: 10.1128/JVI.00872-07. Epub 2007 Jul 18.

设计一种强效的 D-肽 HIV-1 进入抑制剂,具有很强的抗耐药性。

Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance.

机构信息

Department of Biochemistry, University of Utah School of Medicine, 15 N. Medical Drive East, Rm. 4100, Salt Lake City, UT 84112-5650, USA.

出版信息

J Virol. 2010 Nov;84(21):11235-44. doi: 10.1128/JVI.01339-10. Epub 2010 Aug 18.

DOI:10.1128/JVI.01339-10
PMID:20719956
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2953169/
Abstract

The HIV gp41 N-trimer pocket region is an ideal viral target because it is extracellular, highly conserved, and essential for viral entry. Here, we report on the design of a pocket-specific D-peptide, PIE12-trimer, that is extraordinarily elusive to resistance and characterize its inhibitory and structural properties. D-peptides (peptides composed of D-amino acids) are promising therapeutic agents due to their insensitivity to protease degradation. PIE12-trimer was designed using structure-guided mirror-image phage display and linker optimization and is the first D-peptide HIV entry inhibitor with the breadth and potency required for clinical use. PIE12-trimer has an ultrahigh affinity for the gp41 pocket, providing it with a reserve of binding energy (resistance capacitor) that yields a dramatically improved resistance profile compared to those of other fusion inhibitors. These results demonstrate that the gp41 pocket is an ideal drug target and establish PIE12-trimer as a leading anti-HIV antiviral candidate.

摘要

HIV gp41 N-三聚体口袋区域是一个理想的病毒靶点,因为它位于细胞外,高度保守,并且对于病毒进入是必需的。在这里,我们报告了一种口袋特异性 D-肽 PIE12-三聚体的设计,它对耐药性非常难以逃避,并对其抑制和结构特性进行了表征。D-肽(由 D-氨基酸组成的肽)由于对蛋白酶降解的不敏感性而成为有前途的治疗剂。PIE12-三聚体是使用结构导向的镜像噬菌体展示和接头优化设计的,是第一个具有临床应用所需广度和效力的 D-肽 HIV 进入抑制剂。PIE12-三聚体对 gp41 口袋具有超高亲和力,为其提供了结合能(耐药电容器)储备,与其他融合抑制剂相比,其耐药性得到了显著改善。这些结果表明,gp41 口袋是一个理想的药物靶点,并确立了 PIE12-三聚体作为一种领先的抗 HIV 抗病毒候选药物。